9-[(3R)-1-acryloyl-3-piperidinyl]-6-amino-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one | 1351635-63-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 9-[(3R)-1-acryloyl-3-piperidinyl]-6-amino-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one
• 英文别名: (R)-9-(1-acryloylpiperidin-3-yl)-6-amino-7-(4-phenoxyphenyl)-7h-purin-8(9h)-one；6-amino-7-(4-phenoxyphenyl)-9-[(3R)-1-prop-2-enoylpiperidin-3-yl]purin-8-one
• CAS: 1351635-63-6
• 化学式: C₂₅H₂₄N₆O₃
• 分子量: 456.504
• InChiKey: KSUDUUBCXJUFRL-GOSISDBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  105
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• PURINONE DERIVATIVE
  申请人：Yamamoto Shingo

  公开号：US20130079327A1

  公开（公告）日：2013-03-28

  Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.

  由一般公式（I）表示的化合物（公式中的所有符号符合说明中的定义）是除了具有Btk选择性抑制活性外，还表现出优异的代谢稳定性，可以避免肝毒性或类似情况，从而可以为B细胞或肥大细胞参与的疾病提供安全的治疗药物。
• PURINONE DERIVATIVE AS BTK KINASE INHIBITOR
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP3112368A1

  公开（公告）日：2017-01-04

  Compounds represented by general formula (I) as drawn below (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.

  下图中通式（I）所代表的化合物（式中所有符号均符合说明中的定义），除了具有 Btk 选择性抑制活性外，还具有极佳的代谢稳定性，可避免肝毒性等，因此可为 B 细胞或肥大细胞参与的疾病提供安全的治疗剂。
• Purinone derivative
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US10233185B2

  公开（公告）日：2019-03-19

  Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.

  通式（I）所代表的化合物（式中的所有符号均符合说明中的定义）除了具有 Btk 选择性抑制活性外，还具有极佳的代谢稳定性，可避免肝毒性或类似毒性，因此可为 B 细胞或肥大细胞参与的疾病提供安全的治疗剂。
• Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
  申请人：ZHEJIANG DTRM BIOPHARMA CO. LTD.

  公开号：US10596183B2

  公开（公告）日：2020-03-24

  Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.

  本文描述的是癌症（如淋巴恶性肿瘤）和免疫性疾病（如自身免疫性疾病和炎症性疾病）的联合疗法。这些疗法包括联合使用 BTK、mTOR 激酶和 Bcl-2 或其信号通路的抑制剂以及免疫调节药物。还描述了包含这些抑制剂的药物组合物和试剂盒。
• PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES
  申请人：ZHEJIANG DTRM BIOPHARMA CO. LTD.

  公开号：US20170281810A1

  公开（公告）日：2017-10-05

  Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.